Immunotherapy in Acute Myeloid Leukemia: Where We Stand.

ABSTRACT: In the past few years, our improved knowledge of acute myeloid leukemia (AML) pathogenesis has led to the accelerated discovery of new drugs and the development of innovative therapeutic approaches. The role of the immune system in AML development, growth and recurrence has gained increasing interest. A better understanding of immunological escape and systemic tolerance induced by AML blasts has been achieved. The extraordinary successes of immune therapies that harness the power of T cells in solid tumors and certain hematological malignancies have provided new stimuli in this area of research. Accordingly, major efforts have been made to develop immune therapies for the treatment of AML patients. The persistence of leukemia stem cells, representing the most relevant cause of relap

SUBMITTER: Isidori A 

PROVIDER: S-EPMC8143531 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature